Despite the rejection, analysts saw Regeneron’s use of an alternate filler for Eylea HD as a positive development, with BMO Capital Markets noting that this could signal the end of manufacturing ...

GSK now has the global development and commercialisation rights to the COPD-targeting oligonucleotide, EMP-012.

Q3 2025 Earnings Call Transcript October 28, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS ...

The drug dupilumab (Dupixent) effectively clears up airways plugged by mucus during an asthma attack, researchers reported ...

Guggenheim raised the firm’s price target on Regeneron (REGN) to $865 from $815 and keeps a Buy rating on the shares following Q3 performance that ...

Regeneron's Q3 earnings beat forecasts as strong Dupixent profits and rising Eylea HD sales offset a decline in its flagship Eylea brand.

GSK is shelling out $85 million up front, and possibly $745 million overall, for an RNA-based therapy it sees helping a ...

Arcutis Biotherapeutics surged as Q3 earnings beat forecasts and Zoryve sales boomed. Click for my updated look at ARQT stock ...

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

Sanofi extends partnershi[ with Medidata to accelerate clinical trials using AI-powered platforms and remote data collection.